DK3464249T3 - Substituerede carbonnukleosidderivater, der er anvendelige som anticancermidler - Google Patents

Substituerede carbonnukleosidderivater, der er anvendelige som anticancermidler Download PDF

Info

Publication number: DK3464249T3
Authority: DK; Denmark
Prior art keywords: anticancer agents; substituted carbon; derivatives useful; nucleoside derivatives; carbon nucleoside
Prior art date: 2016-06-06

Application number

DK17730948.1T

Other languages

English (en)

Inventor

Robert Arnold Kumpf

Indrawan James Mcalpine

Michele Ann Mctigue

Ryan Patman

Eugene Yuanjin Rui

John Howard Tatlock

Michelle Bich Tran-Dube

Martin James Wythes

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-06-06

Filing date

2017-06-03

Publication date

2021-09-06

2017-06-03 Application filed by Pfizer filed Critical Pfizer

2021-09-06 Application granted granted Critical

2021-09-06 Publication of DK3464249T3 publication Critical patent/DK3464249T3/da

Links

239000002246 antineoplastic agent Substances 0.000 title 1
229910052799 carbon Inorganic materials 0.000 title 1
-1 carbon nucleoside derivatives Chemical class 0.000 title 1
0 *c(cc1)c(CCNC2)c2c1OC(CC([C@@]1O)[n]2c3ncnc(N)c3c(F)c2)[C@@]1O Chemical compound *c(cc1)c(CCNC2)c2c1OC(CC([C@@]1O)[n]2c3ncnc(N)c3c(F)c2)[C@@]1O 0.000 description 4
HLWMUXSNDLXTDJ-FCUIKFHKSA-N Cc1ncnc2c1cc[n]2C(CC([C@H]1O)Oc(cc2Cl)c(CNCC3)c3c2F)[C@@H]1O Chemical compound Cc1ncnc2c1cc[n]2C(CC([C@H]1O)Oc(cc2Cl)c(CNCC3)c3c2F)[C@@H]1O HLWMUXSNDLXTDJ-FCUIKFHKSA-N 0.000 description 1
ARZWYVOXCWPXEV-FCUIKFHKSA-N Cc1ncnc2c1cc[n]2C(CC([C@H]1O)Oc(cc2F)c(CNCC3)c3c2F)[C@@H]1O Chemical compound Cc1ncnc2c1cc[n]2C(CC([C@H]1O)Oc(cc2F)c(CNCC3)c3c2F)[C@@H]1O ARZWYVOXCWPXEV-FCUIKFHKSA-N 0.000 description 1
DRENWEACTABCAJ-PGUJPRLGSA-N Nc1ncnc2c1c(F)c[n]2C(CC(Cc(cc1F)c(CNCC2)c2c1F)[C@H]1O)[C@@H]1O Chemical compound Nc1ncnc2c1c(F)c[n]2C(CC(Cc(cc1F)c(CNCC2)c2c1F)[C@H]1O)[C@@H]1O DRENWEACTABCAJ-PGUJPRLGSA-N 0.000 description 1
ZMPSUNGAEQMZPQ-NWCILSHNSA-N Nc1ncnc2c1c(F)c[n]2C(CC([C@H]1O)Oc2c(CNCC3)c3cc(Br)c2)[C@@H]1O Chemical compound Nc1ncnc2c1c(F)c[n]2C(CC([C@H]1O)Oc2c(CNCC3)c3cc(Br)c2)[C@@H]1O ZMPSUNGAEQMZPQ-NWCILSHNSA-N 0.000 description 1
PIMFJRFYZCJCMY-NWCILSHNSA-N Nc1ncnc2c1c(F)c[n]2C(CC([C@H]1O)Oc2cc(Cl)cc3c2CNCC3)[C@@H]1O Chemical compound Nc1ncnc2c1c(F)c[n]2C(CC([C@H]1O)Oc2cc(Cl)cc3c2CNCC3)[C@@H]1O PIMFJRFYZCJCMY-NWCILSHNSA-N 0.000 description 1
BYRBHMNMDFITQL-PDQHRLGMSA-N Nc1ncnc2c1c(F)c[n]2C(C[C@H](C1O)Oc2cccc3c2CNC3)C1O Chemical compound Nc1ncnc2c1c(F)c[n]2C(C[C@H](C1O)Oc2cccc3c2CNC3)C1O BYRBHMNMDFITQL-PDQHRLGMSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/34—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Silicon Polymers (AREA)
Management, Administration, Business Operations System, And Electronic Commerce (AREA)

DK17730948.1T 2016-06-06 2017-06-03 Substituerede carbonnukleosidderivater, der er anvendelige som anticancermidler DK3464249T3 (da)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201662346226P	2016-06-06	2016-06-06
US201662376856P	2016-08-18	2016-08-18
US201662431714P	2016-12-08	2016-12-08
US201762506076P	2017-05-15	2017-05-15
PCT/IB2017/053295 WO2017212385A1 (en)	2016-06-06	2017-06-03	Substituted carbonucleoside derivatives useful as anticancer agents

Publications (1)

Publication Number	Publication Date
DK3464249T3 true DK3464249T3 (da)	2021-09-06

Family

ID=59071035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17730948.1T DK3464249T3 (da)	2016-06-06	2017-06-03	Substituerede carbonnukleosidderivater, der er anvendelige som anticancermidler

Country Status (42)

Country	Link
US (2)	US10220037B2 (da)
EP (1)	EP3464249B1 (da)
JP (2)	JP6553825B2 (da)
KR (2)	KR102215313B1 (da)
CN (1)	CN109890797B (da)
AU (2)	AU2017279014B2 (da)
BR (1)	BR112018075166A2 (da)
CA (1)	CA2969295A1 (da)
CL (1)	CL2018003504A1 (da)
CO (1)	CO2018013105A2 (da)
CR (1)	CR20180578A (da)
CU (1)	CU24517B1 (da)
CY (1)	CY1124798T1 (da)
DK (1)	DK3464249T3 (da)
DO (1)	DOP2018000268A (da)
EC (1)	ECSP18090743A (da)
ES (1)	ES2890435T3 (da)
GE (1)	GEP20217211B (da)
HR (1)	HRP20211449T1 (da)
HU (1)	HUE056634T2 (da)
IL (2)	IL263505B (da)
LT (1)	LT3464249T (da)
MA (1)	MA45153B1 (da)
MD (1)	MD3464249T2 (da)
MX (1)	MX384948B (da)
MY (1)	MY196413A (da)
NI (1)	NI201800128A (da)
PE (1)	PE20190439A1 (da)
PH (1)	PH12018502535B1 (da)
PL (1)	PL3464249T3 (da)
PT (1)	PT3464249T (da)
RS (1)	RS62351B1 (da)
RU (1)	RU2712944C1 (da)
SG (2)	SG11201810485SA (da)
SI (1)	SI3464249T1 (da)
SV (1)	SV2018005794A (da)
TN (1)	TN2018000424A1 (da)
TW (2)	TWI637945B (da)
UA (1)	UA124386C2 (da)
UY (1)	UY37274A (da)
WO (1)	WO2017212385A1 (da)
ZA (1)	ZA201807723B (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111542525B (zh) *	2017-10-26	2023-06-27	普莱鲁德疗法有限公司	蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
SG11202005112TA (en) *	2017-12-05	2020-06-29	Angex Pharmaceutical Inc	Heterocyclic compounds as prmt5 inhibitors
CN108997309A (zh) *	2018-07-17	2018-12-14	中国科学技术大学苏州研究院	一种吡唑-4-芳基衍生物的制备方法
WO2020033285A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
AU2020211789A1 (en) *	2019-01-23	2021-07-22	Pfizer Inc.	Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative
SG11202110272SA (en)	2019-03-25	2021-10-28	California Inst Of Techn	Prmt5 inhibitors and uses thereof
CA3134613A1 (en) *	2019-04-02	2020-10-08	Aligos Therapeutics, Inc.	Compounds targeting prmt5
CA3141855A1 (en) *	2019-05-30	2020-12-03	Angex Pharmaceutical, Inc.	Heterocyclic compounds as prmt5 inhibitors
CA3141748A1 (en)	2019-06-10	2020-12-17	Lupin Limited	Prmt5 inhibitors
MX2022004145A (es) *	2019-10-07	2022-06-14	De Shaw Res Llc	Compuestos heterociclicos de arilmetileno como bloqueadores del canal de potasio tipo shaker kv1.3.
US20230066014A1 (en) *	2019-12-03	2023-03-02	Lupin Limited	Substituted nucleoside analogs as prmt5 inhibitors
ES2969732T3 (es)	2019-12-18	2024-05-22	Pfizer	Régimen de tratamiento del cáncer una vez al día con un inhibidor de PRMT5
EP4087576A1 (en) *	2020-01-07	2022-11-16	Pfizer Inc.	Prmt5 inhibitor for use in a method of treating psoriasis and other autoimmune conditions
CN111138355A (zh) *	2020-01-17	2020-05-12	成都睿智化学研究有限公司	一种甲醛取代的氮杂稠环类化合物的制备方法
JP2023512000A (ja)	2020-01-31	2023-03-23	ソルヴェイ（ソシエテアノニム）	ハロアルキル置換ピリジン化合物の製造のプロセス
WO2021202480A1 (en) *	2020-04-01	2021-10-07	Aligos Therapeutics, Inc.	Compounds targeting prmt5
WO2022013692A1 (en)	2020-07-15	2022-01-20	Pfizer Inc.	Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
US20240116937A1 (en)	2020-07-15	2024-04-11	Pfizer Inc.	Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
WO2022153161A1 (en)	2021-01-14	2022-07-21	Pfizer Inc.	Treatment of cancer using a prmt5 inhibitor
CN113234079B (zh) *	2021-04-30	2022-02-01	上海湃隆生物科技有限公司	用作prmt5抑制剂的核苷类似物
WO2024118943A2 (en) *	2022-11-30	2024-06-06	Ideaya Biosciences, Inc.	Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor
WO2024170488A1 (en)	2023-02-13	2024-08-22	Astrazeneca Ab	Prmt5 inhibitor for use in cancer therapy
CN121712509A (zh)	2023-05-04	2026-03-20	锐新医药公司	用于ras相关疾病或病症的组合疗法
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
IL327306A (en)	2023-10-12	2026-05-01	Revolution Medicines Inc	Macrocyclic RAS inhibitors
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
WO2025240847A1 (en)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Ras inhibitors
WO2025255438A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026008533A1 (en)	2024-07-01	2026-01-08	Janssen Pharmaceutica Nv	Prmt5 inhibitors for treating adenomas
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026050446A1 (en)	2024-08-29	2026-03-05	Revolution Medicines, Inc.	Ras inhibitors
WO2026072904A2 (en)	2024-09-26	2026-04-02	Revolution Medicines, Inc.	Compositions and methods for treating lung cancer
WO2026090116A2 (en)	2024-10-21	2026-04-30	Revolution Medicines, Inc.	Ras inhibitors
WO2026090245A1 (en)	2024-10-22	2026-04-30	Revolution Medicines, Inc.	Use of ras inhibitors for treating cancer
US20260108528A1 (en)	2024-10-22	2026-04-23	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6143749A (en) *	1995-06-07	2000-11-07	Abbott Laboratories	Heterocyclic substituted cyclopentane compounds
GB9518953D0 (en)	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
WO2000035298A1 (en)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Chewing gum containing medicament active agents
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
IL156915A0 (en)	2001-02-22	2004-02-08	Celltech R&D Ltd	Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors
US20040043959A1 (en) *	2002-03-04	2004-03-04	Bloom Laura A.	Combination therapies for treating methylthioadenosine phosphorylase deficient cells
EP1987717A1 (de)	2007-04-30	2008-11-05	Bayer CropScience AG	Pyridoncarboxamide, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
WO2010100475A1 (en)	2009-03-02	2010-09-10	Astrazeneca Ab	Hydroxamic acid derivatives as gram-negative antibacterial agents
US9216981B2 (en) *	2010-12-02	2015-12-22	Medpacto, Inc.	Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient
WO2013157022A1 (en)	2012-04-20	2013-10-24	Advinus Therapeutics Limited	Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
US8993555B2 (en)	2012-12-21	2015-03-31	Epizyme, Inc.	PRMT5 inhibitors and uses thereof
US20160168185A1 (en)	2013-07-22	2016-06-16	Baylor College Of Medicine	Non-ribose containing inhibitors of histone methyltransferase dot1l for cancer treatment
WO2015200680A2 (en)	2014-06-25	2015-12-30	Epizyme, Inc.	Prmt5 inhibitors and uses thereof
KR20240167709A (ko) *	2015-02-25	2024-11-27	아웃센스 다이아그나스틱스 엘티디.	신체 배출물 분석
TWI791251B (zh)	2015-08-26	2023-02-01	比利時商健生藥品公司	使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物

2017
- 2017-06-01 CA CA2969295A patent/CA2969295A1/en active Pending
- 2017-06-02 US US15/612,030 patent/US10220037B2/en active Active
- 2017-06-03 PE PE2018003140A patent/PE20190439A1/es unknown
- 2017-06-03 KR KR1020197000054A patent/KR102215313B1/ko not_active Expired - Fee Related
- 2017-06-03 EP EP17730948.1A patent/EP3464249B1/en active Active
- 2017-06-03 TN TNP/2018/000424A patent/TN2018000424A1/en unknown
- 2017-06-03 JP JP2018563551A patent/JP6553825B2/ja not_active Expired - Fee Related
- 2017-06-03 HU HUE17730948A patent/HUE056634T2/hu unknown
- 2017-06-03 PL PL17730948T patent/PL3464249T3/pl unknown
- 2017-06-03 MD MDE20190422T patent/MD3464249T2/ro not_active IP Right Cessation
- 2017-06-03 ES ES17730948T patent/ES2890435T3/es active Active
- 2017-06-03 SI SI201730926T patent/SI3464249T1/sl unknown
- 2017-06-03 WO PCT/IB2017/053295 patent/WO2017212385A1/en not_active Ceased
- 2017-06-03 LT LTEPPCT/IB2017/053295T patent/LT3464249T/lt unknown
- 2017-06-03 SG SG11201810485SA patent/SG11201810485SA/en unknown
- 2017-06-03 MY MYPI2018002348A patent/MY196413A/en unknown
- 2017-06-03 SG SG10202100861TA patent/SG10202100861TA/en unknown
- 2017-06-03 MA MA45153A patent/MA45153B1/fr unknown
- 2017-06-03 HR HRP20211449TT patent/HRP20211449T1/hr unknown
- 2017-06-03 CR CR20180578A patent/CR20180578A/es unknown
- 2017-06-03 RU RU2018142734A patent/RU2712944C1/ru active
- 2017-06-03 PT PT177309481T patent/PT3464249T/pt unknown
- 2017-06-03 UA UAA201812060A patent/UA124386C2/uk unknown
- 2017-06-03 KR KR1020217003681A patent/KR20210018529A/ko not_active Ceased
- 2017-06-03 BR BR112018075166-9A patent/BR112018075166A2/pt not_active Application Discontinuation
- 2017-06-03 CN CN201780049070.8A patent/CN109890797B/zh not_active Expired - Fee Related
- 2017-06-03 AU AU2017279014A patent/AU2017279014B2/en not_active Ceased
- 2017-06-03 MX MX2018015094A patent/MX384948B/es unknown
- 2017-06-03 CU CU2018000144A patent/CU24517B1/es unknown
- 2017-06-03 GE GEAP201714948A patent/GEP20217211B/en unknown
- 2017-06-03 DK DK17730948.1T patent/DK3464249T3/da active
- 2017-06-03 RS RS20211156A patent/RS62351B1/sr unknown
- 2017-06-05 TW TW106118476A patent/TWI637945B/zh not_active IP Right Cessation
- 2017-06-05 UY UY0001037274A patent/UY37274A/es not_active Application Discontinuation
- 2017-06-05 TW TW107130452A patent/TWI667240B/zh not_active IP Right Cessation
2018
- 2018-11-16 ZA ZA2018/07723A patent/ZA201807723B/en unknown
- 2018-11-29 PH PH12018502535A patent/PH12018502535B1/en unknown
- 2018-12-04 NI NI201800128A patent/NI201800128A/es unknown
- 2018-12-04 CO CONC2018/0013105A patent/CO2018013105A2/es unknown
- 2018-12-05 IL IL263505A patent/IL263505B/en active IP Right Grant
- 2018-12-06 SV SV2018005794A patent/SV2018005794A/es unknown
- 2018-12-06 CL CL2018003504A patent/CL2018003504A1/es unknown
- 2018-12-06 EC ECSENADI201890743A patent/ECSP18090743A/es unknown
- 2018-12-06 DO DO2018000268A patent/DOP2018000268A/es unknown
- 2018-12-18 US US16/224,016 patent/US10709709B2/en active Active
2019
- 2019-07-04 JP JP2019125220A patent/JP2019194231A/ja active Pending
- 2019-11-15 AU AU2019264640A patent/AU2019264640A1/en not_active Abandoned
2021
- 2021-04-08 IL IL282167A patent/IL282167A/en unknown
- 2021-09-16 CY CY20211100815T patent/CY1124798T1/el unknown

Also Published As

Publication number	Publication date
RS62351B1 (sr)	2021-10-29
AU2019264640A1 (en)	2019-12-05
LT3464249T (lt)	2021-10-11
SG10202100861TA (en)	2021-03-30
PE20190439A1 (es)	2019-03-27
HUE056634T2 (hu)	2022-02-28
IL282167A (en)	2021-05-31
JP2019194231A (ja)	2019-11-07
CY1124798T1 (el)	2022-11-25
JP2019521100A (ja)	2019-07-25
TW201802074A (zh)	2018-01-16
KR20190015745A (ko)	2019-02-14
DOP2018000268A (es)	2019-01-31
UY37274A (es)	2018-01-31
EP3464249A1 (en)	2019-04-10
GEP20217211B (en)	2021-01-25
TW201840570A (zh)	2018-11-16
MA45153B1 (fr)	2021-10-29
PL3464249T3 (pl)	2021-12-20
US10220037B2 (en)	2019-03-05
CU20180144A7 (es)	2019-07-04
IL263505A (en)	2019-01-31
AU2017279014B2 (en)	2019-08-15
TWI667240B (zh)	2019-08-01
CO2018013105A2 (es)	2018-12-28
CU24517B1 (es)	2021-06-08
IL263505B (en)	2021-04-29
SV2018005794A (es)	2019-03-19
BR112018075166A2 (pt)	2019-03-26
ECSP18090743A (es)	2019-01-31
TN2018000424A1 (en)	2020-06-15
CL2018003504A1 (es)	2019-02-01
CN109890797B (zh)	2023-02-28
RU2712944C1 (ru)	2020-02-03
MA45153A (fr)	2021-04-07
KR20210018529A (ko)	2021-02-17
MX2018015094A (es)	2019-08-16
NZ748652A (en)	2021-06-25
US20170348313A1 (en)	2017-12-07
CA2969295A1 (en)	2017-12-06
CN109890797A (zh)	2019-06-14
HRP20211449T1 (hr)	2021-12-24
PH12018502535B1 (en)	2022-08-19
JP6553825B2 (ja)	2019-07-31
PT3464249T (pt)	2021-09-22
CR20180578A (es)	2019-03-05
EP3464249B1 (en)	2021-08-11
WO2017212385A1 (en)	2017-12-14
KR102215313B1 (ko)	2021-02-17
NI201800128A (es)	2019-04-08
UA124386C2 (uk)	2021-09-08
US20190111060A1 (en)	2019-04-18
SI3464249T1 (sl)	2021-11-30
SG11201810485SA (en)	2018-12-28
MX384948B (es)	2025-03-11
ES2890435T3 (es)	2022-01-19
US10709709B2 (en)	2020-07-14
ZA201807723B (en)	2020-01-29
AU2017279014A1 (en)	2018-12-13
MD3464249T2 (ro)	2021-12-31
TWI637945B (zh)	2018-10-11
PH12018502535A1 (en)	2019-10-21
MY196413A (en)	2023-03-29

Publication	Publication Date	Title
ZA201705092B (en)	2019-06-26	Substituted nucleoside derivatives useful as anticancer agents
IL256898A (en)	2018-03-29	Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
ZA201807723B (en)	2020-01-29	Substituted carbonucleoside derivatives useful as anticancer agents
DK3122752T3 (da)	2021-10-25	4'-substituerede nukleosidderivater som hiv-reverse transskriptasehæmmere
DK3461821T3 (da)	2020-08-17	Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
BR112017005122A2 (pt)	2018-07-31	derivados tetracíclicos ativos em termos pesticidas com substituintes contendo enxofre.
HUE058009T2 (hu)	2022-06-28	1,3-Tiazol-2-il szubsztituált benzamid-származékok
DK3319956T3 (da)	2021-03-29	Substituerede oxopyridinderivater
DK3609898T3 (da)	2022-09-05	Forbindelser, der er nyttige som ret-hæmmere
DK3094631T4 (da)	2025-03-03	Pyrimidinyloxybenzenderivater som herbicider
DK3464309T3 (da)	2020-06-29	Phosphoramidatnukleosidderivater som anticancermidler
DK3313838T3 (da)	2019-06-11	Polycykliske amidderivater som cdk9-inhibitorer
DK3313832T3 (da)	2021-04-19	3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere
DK3582780T3 (da)	2021-11-01	Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer
DK3235819T3 (da)	2020-12-07	Pyrrolopyrimidinforbindelser, der er anvendelige som JAK-inhibitorer
DK3253762T3 (da)	2021-07-19	9h-pyrrolo-dipyridinderivater.
MA39822A (fr)	2018-02-06	Dérivés de pyrimidine bicycle
LT3168219T (lt)	2021-06-25	Piridono dariniai, turintys tetrahidropiranilmetilo grupę
EP3457851A4 (en)	2020-02-26	DERIVATIVES OF SOBETIROM
DK3319597T3 (da)	2021-04-06	Sammensætninger, der omfatter antistof-duocarmycin-lægemiddelkonjugater
DK3672951T3 (da)	2023-11-20	Quinoxalinderivater som adenosinreceptorantagonister
DK3153508T3 (da)	2020-05-18	Naphthofuranderivater til anvendelse som anticancermidler
DK3126486T3 (da)	2019-10-14	Immunassay, der benytter indfangningskonjugat
LT3402782T (lt)	2020-10-12	8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai
DK3552017T3 (da)	2022-05-16	Forbindelser, der er anvendelige som ripk1-inhibitorer